| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd348f97a66b7b5c263168f885f26107 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
| filingDate |
2020-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6f0b0e88245bc2c38a873ef69ac717d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca42c0d60d729adb50adac3da9c87ab9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_731d06dd0da75de22a437f4346b36b34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30fe171b16896f2c46b67027ee7a3715 |
| publicationDate |
2021-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021087171-A1 |
| titleOfInvention |
Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
| abstract |
The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115894450-A |
| priorityDate |
2019-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |